Erratum: Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation (Oncogene (2006) 25, (7618-7634) DOI: 10.1038/sj.onc.1209738);Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation

Oncogene

Volumn 25, Issue 58, 2006, Pages 7618-7634

  Hamai A ^a   Richon, C ^a   Meslin, F ^a   Faure, F ^b   Kauffmann, A ^c   Lecluse, Y ^c   Jalil, A ^a   Larue, L ^b   Avril, M F ^c   Chouaib, S ^a   Mehrpour, M ^a,d  

^a INSERM   (France)

^b INSTITUT CURIE   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d INSTITUTE OF ZOOLOGY   (China)

Author keywords

Apoptosis; Gene expression profiling; Human melanoma; Metastasis; TRAIL; Tyrosine kinase

Indexed keywords

ABELSON KINASE; ADENOSINE TRIPHOSPHATE; CASPASE; CASPASE 8; CASPASE 9; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOCHROME C; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; STEM CELL FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL CLONE; CELL DEATH; CELL PROLIFERATION; CELL STRAIN; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MELANOMA CELL; METASTASIS; MICROARRAY ANALYSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 33845523836     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210213     Document Type: Erratum

References (60)

1. Al-Shahrour F, Diaz-Uriarte R, Dopazo J. (2004). Bioinformatics 20: 578-580.
2. All-Ericsson C, Girnita L, Muller-Brunotte A, Brodin B, Seregard S, Ostman A et al. (2004). Invest Ophthalmol Vis Sci 45: 2075-2082.
3. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. (1999). J Clin Invest 104: 155-162.
4. Barnhart BC, Lee JC, Alappat EC, Peter ME. (2003). Oncogene 22: 8634-8644.
5. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M et al. (2000). Nature 406: 536-540.
6. Carcelain G, Rouas-Freiss N, Zorn E, Chung-Scott V, Viel S, Faure F et al. (1997). Int J Cancer 72: 241-247.
7. Carr KM, Bittner M, Trent JM. (2003). Oncogene 205722: 3076-3080.
8. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB et al. (1997). Blood 90: 4947-4952.
9. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. (2004). Cell Death Differ 11: 915-923.
10. Clark EA, Golub TR, Lander ES, Hynes RO. (2000). Nature 406: 532-535.
11. Cory GO, Ridley AJ. (2002). Nature 418: 732-733.
12. Debatin KM, Krammer PH. (2004). Oncogene 23: 2950-2966.
13. Decaudin D, de Cremoux P, Sastre X, Judde JG, Nemati F, Tran-Perennou C et al. (2005). Int J Cancer 113: 849-856.
14. Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S et al. (1999). J Cell Biol 144: 891-901.
15. Diarra-Mehrpour M, Arrabal S, Jalil A, Pinson X, Gaudin C, Pietu G et al. (2004). Cancer Res 64: 719-727.
16. Druker BJ. (2002). Oncogene 21: 8541-8546.
17. Dufour E, Carcelain G, Gaudin C, Flament C, Avril MF, Faure F. (1997). J Immunol 158: 3787-3795.
18. El-Deiry WS. (2001). Cell Death Differ 8: 1066-1075.
19. Eriksson L, Antti H, Gottfries J, Holmes E, Johansson E, Lindgren F et al. (2004). Anal Bioanal Chem 380: 419-429.
20. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC et al. (2004). Cell Death Differ 11(Suppl 1): S86-S96.
21. Gross A, McDonnell JM, Korsmeyer SJ. (1999). Genes Dev 13: 1899-1911.
22. Hasegawa J, Kamada S, Kamiike W, Shimizu S, Imazu T, Matsuda H et al. (1996). Cancer Res 56: 1713-1718.
23. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. (2000). Blood 96: 925-932.
24. Hersey P, Zhang XD. (2001). Nat Rev Cancer 1: 142-150.
25. Hodgkinson CA, Nakayama A, Li H, Swenson LB, Opdecamp K, Asher Jr JH et al. (1993). Cell Death Differ 74: 395-404.
26. Ivanov VN, Bhoumik A, Ronai Z. (2003). Oncogene p205722: 3152-3161.
27. Ivanov VN, Hei TK. (2005). Oncogene 24: 616-626.
28. Jin TG, Kurakin A, Benhaga N, Abe K, Mohseni M, Sandra F et al. (2004). J Biol Chem 279: 55594-55601.
29. Johnston JB, Kabore AF, Strutinsky J, Hu X, Paul JT, Kropp DM et al. (2003). Oncogene 22: 8356-8369.
30. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J et al. (2001). J Pharmacol Exp Ther 299: 31-38.
31. Kim KM, Lee YJ. (2005). Oncogene 24: 355-366.
32. Kroemer G, Zamzami N, Susin SA. (1997). Immunol Today 18: 44-51.
33. Krueger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S. (2001). J Biol Chem 276: 20633-20640.
34. Krystal GW, Honsawek S, Litz J, Buchdunger E. (2000). Clin Cancer Res 6: 3319-3326.
35. LeBlanc HN, Ashkenazi A. (2003). Cell Death Differ 10: 66-75.
36. Lefevre G, Glotin AL, Calipel A, Mouriaux F, Tran T, Kherrouche Z et al. (2004). J Biol Chem 279: 31769-31779.
37. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. (2002). Cancer Cell 2: 183-192.
38. Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH et al. (2000). Cancer Res 60: 553-559.
39. Mikhailov V, Mikhailova M, Degenhardt K, Venkatachalam MA, White E, Saikumar P. (2003). J Biol Chem 278: 5367-5376.
40. Muhlethaler-Mottet A, Bourloud KB, Auderset K, Joseph JM, Gross N. (2004). Oncogene 23: 5415-5425.
41. Nesterov A, Ivashchenko Y, Kraft AS. (2002). Oncogene 21: 1135-1140.
42. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. (2001). J Biol Chem 276: 10767-10774.
43. Nimmanapalli R, Bhalla K. (2002). Oncogene 21: 8584-8590.
44. Pandiella A, Carvajal-Vergara X, Tabera S, Mateo G, Gutierrez N, San Miguel JF. (2003). Br J Haematol 123: 858-868.
45. Poncet D, Larochette N, Pauleau AL, Boya P, Jalil AA, Cartron PF et al. (2004). J Biol Chem 279(7): 22605-22614.
46. Sattler M, Salgia R. (2004). Leuk Res 28(Suppl 1): S11-S20.
47. Soengas MS, Lowe SW. (2003). Oncogene 22: 3138-3151.
48. Strasser A. (2005). Nat Rev Immunol 5: 189-200.
49. Taylor JR, Brownlow N, Domin J, Dibb NJ. (2006). Oncogene 25: 147-151.
50. Thomas WD, Zhang XD, Franco AV, Nguyen T, Hersey P. (1998). J Immunol 161: 2195-2200.
51. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F et al. (1997). Nature 386: 517-521.
52. Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J et al. (2005). Br J Cancer 92: 1881-1891.
53. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. (1999). Nat Med 5: 157-163.
54. Wang S, El-Deiry WS. (2003). Oncogene 22: 8628-8633.
55. Weeraratna AT, Becker D, Carr KM, Duray PH, Rosenblatt KP, Yang S et al. (2004). Oncogene 23: 2264-2274.
56. Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M et al. (2000). Genes Dev 14: 2060-2071.
57. Wendt J, von Haefen C, Hemmati P, Belka C, Dorken B, Daniel PT. (2005). Oncogene 24: 4052-4064.
58. Wittnebel S, Jalil A, Thiery J, DaRocha S, Viey E, Escudier B et al. (2005). Eur Cytokine Netw 16: 123-127.
59. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. (2004). Cancer Sci 95: 777-783.
60. Yamaguchi K, Uzzo RG, Pimkina J, Makhov P, Golovine K, Crispen P et al. (2005). Oncogene 24: 5868-5877.